FABRX has started a fully automated approach to pharmacy compounding and has moved into real-world production, with the FABRX M3DIMAKER demonstrating large-scale pharmaceutical 3D printing capabilities during a continuous 24-hour manufacturing workflow. The company said the system successfully produced and validated more than 10,000 capsules in a single day, with every capsule containing a personalized dose. According to the announcement, the achievement marks a shift from experimental demonstrations to operational pharmacy-scale production using the M3DIMAKER platform.
The company described the development as a major step forward for precision medicine and pharmacy operations, emphasizing that the process is no longer limited to theoretical concepts or pilot-stage testing.
The M3DIMAKER integrates pharmaceutical 3D printing, automated capsule filling, and built-in quality control into a single continuous workflow designed to improve efficiency while maintaining dosing precision. The system operated throughout the 24-hour run with minimal human intervention while preserving consistent dose control across thousands of capsules.
Traditional capsule compounding methods have long presented challenges for pharmacies due to labour-intensive preparation processes, variability in production, and difficulties associated with scaling personalized medicine. The company said those limitations are addressed through the M3DIMAKER system, where every capsule is printed and filled according to digitally defined parameters. This approach is intended to support accuracy, traceability, and reproducibility at scale while reducing operational bottlenecks tied to personalized dosing.
The company also highlighted operational benefits linked to automation within the M3DIMAKER workflow. By reducing manual handling during production, pharmacies can lower exposure to APIs while expanding personalized dosing capabilities without increasing staff workload. The automated system is also designed to free pharmacists from time-consuming compounding tasks, allowing more focus on clinical responsibilities and patient-facing care. The company described the platform as “the missing link between precision medicine and real-world pharmacy operations.”
